Kenney CT, Marraffini LA.  2023.  Rarely acquired type II-A CRISPR-Cas spacers mediate anti-viral immunity through the targeting of a non-canonical PAM sequence.. Nucleic Acids Res. 51(14):7438-7450.

Nussenzweig PM, Marraffini LA.  2018.  Viral Teamwork Pushes CRISPR to the Breaking Point.. Cell. 174(4):772-774.

Keen EC.  2015.  A century of phage research: bacteriophages and the shaping of modern biology.. Bioessays. 37(1):6-9.

Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, Fischetti VA, Marraffini LA.  2014.  Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.. Nat Biotechnol. 32(11):1146-50.

Hyde-DeRuyscher R, Paige LA, Christensen DJ, Hyde-DeRuyscher N, Lim A, Fredericks ZL, Kranz J, Gallant P, Zhang J, Rocklage SM et al..  2000.  Detection of small-molecule enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries.. Chem Biol. 7(1):17-25.